Thrombosis and Haemostasis

Journal Information
ISSN / EISSN : 0340-6245 / 2567-689X
Current Publisher: Georg Thieme Verlag KG (10.1055)
Former Publisher: Georg Thieme Verlag KG (10.1160)
Total articles ≅ 17,405
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Filter:

Latest articles in this journal

James D. McFadyen, Karlheinz Peter
Thrombosis and Haemostasis; doi:10.1055/s-0040-1718533

The publisher has not yet granted permission to display this abstract.
Simona Costanzo, Roberta Parisi, Amalia De Curtis, Sara Gamba, Laura Russo, Mariarosaria Persichillo, Teresa Panzera, Marina Marchetti, Chiara Cerletti, Giovanni De Gaetano, et al.
Thrombosis and Haemostasis; doi:10.1055/s-0040-1718531

The publisher has not yet granted permission to display this abstract.
Farah Abdel Rahman, Sascha D'almeida, Tina Zhang, Morad Asadi, Tarik Bozoglu, Dario Bongiovanni, Moritz Von Scheidt, Steffen Dietzel, Edzard Schwedhelm, Rabea Hinkel, et al.
Thrombosis and Haemostasis; doi:10.1055/s-0040-1716844

The publisher has not yet granted permission to display this abstract.
Alexander P. Benz, John W. Eikelboom, Salim Yusuf, Stefan H. Hohnloser, Anja Kahl, Heather Beresh, Kumar Balasubramanian, Jeff S. Healey, Stuart J. Connolly
Thrombosis and Haemostasis; doi:10.1055/s-0040-1717115

Abstract:
Background AVERROES, a randomized controlled trial in high-risk patients with atrial fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of apixaban compared with aspirin. At the conclusion of the double-blind phase, an open-label extension was initiated to allow study participants to receive apixaban until it became locally available. This study reports outcomes of patients on apixaban during the open-label extension. Methods Rates of stroke or systemic embolism, hemorrhagic stroke, major bleeding, and other outcomes during the open-label extension are reported. Results Of the 5,599 participants enrolled in AVERROES, 3,275 (58.5%) received apixaban during the open-label extension. Median (interquartile range) follow-up in the open-label extension was 3.0 (2.5–3.5) years. The rate of stroke or systemic embolism during the open-label extension was 1.0% per year, and the annual rates of hemorrhagic stroke and major bleeding were 0.3 and 1.2%, respectively. After adjustment for imbalances in patient variables, event rates in patients on apixaban during the open-label extension were similar to those of patients receiving apixaban during AVERROES. Additional analyses in all patients who received apixaban, at any time from the start of AVERROES to the end of the open-label extension, were performed. This cohort (n = 4,414) showed annual event rates of 1.1% for stroke or systemic embolism, 0.3% for hemorrhagic stroke, and 1.2% for major bleeding. Conclusion During the open-label extension, annual rates of stroke or systemic embolism, hemorrhagic stroke, and major bleeding remained as low as those observed during apixaban treatment in AVERROES. These data support the long-term efficacy and safety of apixaban in patients with atrial fibrillation.
Karen Aymonnier, Charlotte Kawecki, Véronique Arocas, Yacine Boulaftali, Marie Christine Bouton
Published: 28 September 2020
Thrombosis and Haemostasis; doi:10.1055/s-0040-1716751

The publisher has not yet granted permission to display this abstract.
Published: 24 September 2020
Thrombosis and Haemostasis; doi:10.1055/s-00035024

Hung-Yi Chiou, Chyi-Huey Bai, Li-Ming Lien, Chaur-Jong Hu, Jiann-Shing Jeng, Sung-Chun Tang, Huey-Juan Lin, Yi-Chen Hsieh
Published: 22 September 2020
Thrombosis and Haemostasis; doi:10.1055/s-0040-1717116

The publisher has not yet granted permission to display this abstract.
Grigoris T. Gerotziafas, Theodoros N. Sergentanis, Guillaume Voiriot, Ludovic Lassel, Chryssa Papageorgiou, Alexandre Elabbadi, Matthieu Turpin, Patrick Vandreden, Loula Papageorgiou, Theodora Psaltopoulou, et al.
Published: 22 September 2020
Thrombosis and Haemostasis; doi:10.1055/s-0040-1716544

The publisher has not yet granted permission to display this abstract.
Kevin T. Trigani, Scott L. Diamond
Published: 22 September 2020
Thrombosis and Haemostasis; doi:10.1055/s-0040-1715648

The publisher has not yet granted permission to display this abstract.
Jiansong Huang, Shujuan Huang, Zhixin Ma, Xiangjie Lin, Xia Li, Xin Huang, Jinghan Wang, Wenle Ye, Yang Li, Daqiang He, et al.
Published: 22 September 2020
Thrombosis and Haemostasis; doi:10.1055/s-0040-1716530

The publisher has not yet granted permission to display this abstract.
Back to Top Top